Search

Your search keyword '"Vose, Julie M"' showing total 2,004 results

Search Constraints

Start Over You searched for: Author "Vose, Julie M" Remove constraint Author: "Vose, Julie M"
2,004 results on '"Vose, Julie M"'

Search Results

201. Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

202. Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma

204. Mitigating the Risk of Cytokine Release Syndrome (CRS): Preliminary Results from a DLBCL Cohort of Epcore NHL-1

205. Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

206. Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

207. Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

208. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma

213. Molecular diagnosis of Burkitt's lymphoma

215. A novel MYC –non ‐ IG fusion in refractory diffuse large B‐cell lymphoma

216. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma

218. Two Step Anti-Thymocyte Globulin (ATG) Is Associated with No Severe Acute Graft Versus Host Disease and Favorable Immune Reconstitution Post Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

219. Prophylactic Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)

220. Assessment of Time to CAR-T Cell Therapy and Patients’ Outcomes in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Based on Insurance Status (Public Versus Private) and Distance Traveled to Treatment Center

221. Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access (EA) and Commercial out-of-Specification (OOS) Product

222. LEADing the Way: Leadership, Empowerment, and Development Conference

223. Addressing Stress and Burnout in Hematology/Oncology Physicians

227. Contributors

229. Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement

235. Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma

237. A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic Leukemia.

247. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project

248. The Future of Telehealth for Hematology/Oncology Care

249. The Future of Oncology: Supply and Demand for Oncology Services

Catalog

Books, media, physical & digital resources